Hereditary transthyretin amyloidosis (ATTRv)

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Cardiology

Background:

• Hereditary transthyretin amyloidosis (ATTRv amyloidosis) is a severe, multisystem disorder with variable clinical presentations, including neurological, cardiac, and mixed phenotypes.
• Phenotypic heterogeneity historically impeded prompt diagnosis and risk assessment, particularly in patients lacking family history.
• Recent advancements in noninvasive diagnostics have improved awareness and facilitated earlier disease identification.

Purpose of the Study:

• To provide an updated review of hereditary transthyretin amyloidosis (ATTRv amyloidosis).
• To emphasize the critical role of early diagnosis in leveraging therapeutic advancements.
• To discuss current and emerging management strategies for ATTRv amyloidosis.

Main Methods:

• Literature review of recent studies on ATTRv amyloidosis mechanisms, diagnosis, and treatment.
• Analysis of current therapeutic approaches including TTR stabilizers, gene silencers, and amyloid removal agents.
• Exploration of CRISPR gene editing as a potential curative strategy.

Main Results:

• Noninvasive testing has enhanced diagnostic capabilities, leading to earlier detection of ATTRv amyloidosis.
• Approved therapies effectively manage disease progression by stabilizing TTR, silencing TTR variants, or removing amyloid deposits.
• CRISPR gene editing technology presents a groundbreaking potential for a curative treatment.

Conclusions:

• Early diagnosis of ATTRv amyloidosis is paramount for effective patient management.
• A combination of advanced diagnostics and novel therapeutics, including gene editing, is transforming the outlook for patients.
• Continued research and clinical application of these advances are crucial for improving patient outcomes.